# A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

NCT06853444

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 1, Phase 2 |
| **Sponsor** | Shanghai Escugen Biotechnology Co., Ltd |
| **Enrollment** | 84 participants |

## Key Eligibility Criteria

### Inclusion (8)

- \. Willing and able to provide written informed consent for this trial.
- \. Male or female, age e 18 years on the day of signing the informed consent form.
- \. Diagnosed with primary immune thrombocytopenia (ITP), and having received treatment of corticosteroids ± intravenous immunoglobulin (IVIG) in the past.
- \. At the time of the last ITP treatment, loss of response, insufficient response, no response or intolerance occurred.
- \. At screening, Platelet Count revealed \< 30 * 10\^9/L twice (with an interval of at least 24 hours between the two tests).

... and 3 more (see full listing online)

### Exclusion (21)

- \. Diagnosed with secondary immune thrombocytopenia, or there is evidence that the patient has a secondary cause of immune thrombocytopenia, or the patient has multiple immune cytopenias.
- \. Previously received B-cell depletion therapy (e.g., rituximab, Ianalumab, etc.).
- \. Received platelet transfusion or whole blood transfusion, plasma exchange, or any other rescue treatment within 14 days before the first administration of the trial drug.
- \. Participated in other investigational drug clinical studies within 4 weeks before the first administration of the investigational drug or within 5 half-lives of the investigational drug received (whichever is longer).
- \. Underwent splenectomy within 12 weeks before the first administration of the investigational drug.

... and 16 more (see full listing online)

## Locations (1 total)

Qilu Hospital of Shandong University, Jinan, Shandong, China